MD, PhD, Lead Thoracic Oncol. Unit @hospitalclinic, MedOnc, Prof. @unibarcelona, Researcher Transl Genom 🧬 Targeted Therapies @IDIBAPS, @EORTC @GECP_org, #LCSM
Sitges, España
Joined March 2017
- Tweets4.4K
- Following611
- Followers3.6K
- Likes10.2K
Pinned Tweet
Looking forward to this new Meet the Professor in Thoracic Tumors virtual session! It will be a pleasure to have professor @peters_solange sharing the latest developments in thoracic oncology. Together with @EnriquetaFelip, we are delighted to have you join us on September 22!
LAST CALL 💻 Meet the Professor in Thoracic Tumors: @peters_solange
On September 22, Dr. Solange Peters will lead a new virtual session focused on the latest developments in thoracic tumors.
🩺 Scientific coordination: Dr. @EnriquetaFelip and Dr. @NReguart
📅 September 22 · Virtual
Programme and registration ⤵️
tacticsmd.net/actividad/vii-…
#ThoracicTumors #LungCancer #Oncology #MedicalEducation
Noemi Reguart retweeted
#ESMO President @FAndreMD explains the relevance of #ESMO26 in the information age: a Congress where the latest #CancerResearch and #ScientificInnovation converge and the #oncology community gathers to discuss and interpret new research.
#InsightsbyESMO ➡️ esmo.org/insights-by-esmo/al…
First day at #ESMO26!
Exceptional international faculty @EnriquetaFelip, Dr. Antonio Passaro, @MARIANOPROVENCI and Maria Karen, exploring the many facets of NSCLC management, always keeping patients’ preferences at the heart of decision-making. Full house at #ESMO26!
How important it is to hear the surgeon’s perspective on defining resectability and its challenges! Excellent insights from Dr. Stiles @BrendonStilesMD at the Expert Meeting on Non-Metastatic NSCLC. #Madrid @peters_solange @FedericoCappuz1
Noemi Reguart retweeted
👀 Phase 1b FURTHER trial @Cancer_Cell : 1L firmonertinib opens promising new horizons for rare #EGFR PACC mutant #NSCLC with a 68% response rate, a 16 mo mPFS, and a 47% intracranial response rate. Strong potential for this hard-to-treat EGFR mutation! @LeXiuning
Noemi Reguart retweeted
Phase III FURVENT trial of 1L firmonertinib monotherapy vs pemetrexed-based chemo does not meet primary endpoint of PFS in pts with EGFR exon 20 insertion mutant NSCLC. Press release notes OS trend and clinical benefit by RR and PFSinv. Await full data.
ir.arrivent.com/news-release…
Noemi Reguart retweeted
Phase II ETOP 18-21 AMAZE-lung trial of 2L amivantamab + lazertinib + bevacizumab after 3G TKI in EGFR NSCLC @LancetRespirMed. RR 39%. TRAEs included infusion reaction 58%, rash 50%, VTE 17% which would likely be mitigated with SQ and modern support.
thelancet.com/journals/lanre…
Noemi Reguart retweeted
Why attend the ESMO Clinical Practice Guidelines Session at #ESMO26?
“It helps you put guidelines into clinical context and make them relevant to your practice.” @DrSanjayPopat
📆Add it to your agenda: ow.ly/82oS50ZXTs0
@RuhlmannC
Noemi Reguart retweeted
ESMO Fellowship session at #ESMO26: stories, perspectives, hopes and reflections from past and present fellows. A unique source of inspiration for #YoungOncologists.
🔗 ow.ly/JJFE50ZXG1N
#ESMOFellowships #CareerDevelopment
Noemi Reguart retweeted
"The session “Beyond guidelines: Expert navigation through the grey zone of oncology practice” at #ESMO26 explores the complexities of clinical decision-making across oncology practice.
➡️ow.ly/CHhb50ZY3NB
@AndriPapakonst @AliceIndini
Noemi Reguart retweeted
Step-up dosing, monitoring after the first doses, and early recognition of cytokine release syndrome and neurological events: giving DLL3-targeted TCEs takes a trained team.
Giannis Mountzios, of Henry Dunant Hospital Center, Athens, covers the practice at our ESMO 2026 Industry Satellite Symposium, Sunday 25 October from 13:00. Come and meet him in the Salamanca Auditorium, Hall 10, and send your question ahead at grillspeakers.com. We would be glad to have you with us 🙂
@peters_solange @MartinReck2 @g_mountzios @NReguart
Add it to your calendar: lungsummit.org/calendar/sclc…
Programme and faculty: lungsummit.org/featured/sclc…
#ESMO26 #SCLC #LungCancer
Noemi Reguart retweeted
Where ICIs, DLL3-targeted TCEs and ADCs each fit in SCLC depends on when a patient relapses and what came before. Noemí Reguart speaks on sequencing at our ESMO 2026 symposium, Sunday 25 October from 13:00. Send your sequencing question ahead at grillspeakers.com. We would love to meet you in the Salamanca Auditorium, Hall 10 🙂
@peters_solange @MartinReck2 @g_mountzios @NReguart
Add it to your calendar: lungsummit.org/calendar/sclc…
Programme and faculty: lungsummit.org/featured/sclc…
#ESMO26 #SCLC #LungCancer
Noemi Reguart retweeted
DLL3-targeted TCEs, from the first results in relapsed SCLC to the trials now testing them in first line: Solange Peters takes this on at our ESMO 2026 symposium, Sunday 25 October from 13:00. Send her your question ahead at grillspeakers.com. We hope to welcome you in the Salamanca Auditorium, Hall 10, so add it to your calendar if you have not yet 🙂
@peters_solange @MartinReck2 @g_mountzios @NReguart
Add it to your calendar: lungsummit.org/calendar/sclc…
Programme and faculty: lungsummit.org/featured/sclc…
#ESMO26 #SCLC #LungCancer
Noemi Reguart retweeted
A DLL3-targeted TCE has improved overall survival over chemotherapy after first-line treatment in SCLC, consolidation ICI has entered practice in limited-stage disease, and ADCs are in trials. Martin Reck opens the talks at our ESMO 2026 symposium on Sunday 25 October. We would be delighted to see you. We start at 13:00 in the Salamanca Auditorium, Hall 10.
@peters_solange @MartinReck2 @g_mountzios @NReguart
Add it to your calendar: lungsummit.org/calendar/sclc…
Programme and faculty: lungsummit.org/featured/sclc…
#ESMO26 #SCLC #LungCancer
Noemi Reguart retweeted
🫁 #WCLC26 recap: Subcutaneous tarlatamab shows promising antitumor activity, safety profile in ES-SCLC.
🔗 Read the presentation highlights in ILCN: bit.ly/4hots0D
#LCSM
Noemi Reguart retweeted
Looking forward to an eventful #ESMO26!
Sunday, 25 October, at 1pm CEST, join Drs. @APassaroMD @Tony_Calles @HendriksLizza and me in IFEMA Hall 4 as we discuss the rapidly evolving treatment landscape for EGFR mutant NSCLC.
Noemi Reguart retweeted
Our Top 10 #LungCancer abstracts for #ESMO26 in Madrid.
All ten are late-breakers, all in Alicante Auditorium, Hall 6, Sat 24 to Mon 26 Oct.
Import them all to your calendar: lungsummit.org/wp-content/up…
Presenting: @sands_jacob @peters_solange @FSkoulidis, with colleagues in Shanghai and Guangzhou.
Which are on your list? #LCSM @myESMO
ALT Lung Summit card listing the Top 10 lung cancer late-breaking abstracts at ESMO 2026 in Madrid, 24 to 26 October, with session times, rooms and presenters.
Noemi Reguart retweeted
👉 In this #ESMOGuidelines webinar, we explore the ESMO Clinical Practice Guidelines for early stage and locally advanced #NSCLC, applying key recommendations to a real-world case in multidisciplinary #LungCancer care
🔗 ow.ly/M9JO50ZRjOW
Noemi Reguart retweeted
Solange Peters (@peters_solange), Rolf A. Stahel, Giannis Mountzios (@g_mountzios), Antonio Passaro (@APassaroMD), Noemí Reguart (@NReguart), Jordi Remon (@JordiRemon) and further colleagues set out where ADC research should go next.
🔬 @etop_ibcsg position statement on ADC research priorities across solid tumours, ESMO Open
📌 Tailor priorities by tumour type, starting where an ADC could replace chemotherapy
📌 Meet prespecified criteria on patient numbers and efficacy before moving from phase I to phase III
📌 Identify, develop and validate predictive biomarkers, with AI as one route to composite markers
Read our article on why several ADCs got there with no mandatory biomarker.
lungsummit.org/articles/anti…
Noemi Reguart retweeted
An unfortunate development in a SCLC landscape where post-tarlatamab, few approved options. Would not read too much into the withdrawal - need to wait for phase III results as phase II likely inadequate. The B7-H3 class holds great promise with tam-peli, ris-rez, & I-DXd.
Quite a surprise, I-dxd BLA application withdrawn. The wait for an ADC for small cell lung cancer outside China will continue, disappointing news #lcsm stocktitan.net/news/MRK/ifin…
